Pulse ·

Australia's breast screening is changing: what dense breasts mean now

By Dr HB Lo, FACRRM 4 min read
Verdict Yes — worth knowing about

Australia's BreastScreen program is moving toward risk-stratified screening — personalising mammography based on individual risk profile, not age alone. A national review recommends all screened women be notified of their breast density, and that tools like iPrevent and CanRisk guide follow-up for those at higher risk.

The changes will roll out over ten years, with AI mammography pilots underway in Victoria and South Australia. If you are over 40, talking to your GP about your personal risk factors — family history, breast density, and whether genetic testing is relevant — is worth doing now, ahead of the formal rollout.

What just happened

Australia’s breast cancer screening framework is changing. A national review of the BreastScreen Australia program has recommended a decade-long shift from age-based screening to risk-stratified screening — meaning the type and frequency of mammography you are offered will be personalised to your individual risk profile, rather than your age alone.

The review, published this week and summarised by University of Western Australia researcher Jennifer Stone in The Conversation, recommends that all women attending BreastScreen be notified of their breast density at their screening visit. Women with dense breast tissue, family histories of breast or ovarian cancer, or elevated polygenic risk scores would be offered more intensive surveillance — more frequent mammograms, additional ultrasound, or MRI in high-risk cases.

AI-powered mammography tools trained on Australian data are already being trialled in Victoria and South Australia. The aim is to use these systems to identify cancers that standard mammographic review can miss, particularly in women with dense breast tissue where the technology has historically underperformed.

The timeline is ten years. This is not immediate. But the conversation that will drive whether you benefit from this shift? That can happen now.

Both-and

The case for change is solid

The current BreastScreen system invites women aged 50 to 74 for a free mammogram every two years. It was designed when the tools for risk stratification did not exist at population scale. The logic was reasonable then: screen often, screen everyone in the age band, and you will catch most cancers.

The problem is that breast cancer is not distributed evenly across that age band. A 52-year-old woman with fatty breast tissue and no family history faces a meaningfully different risk to a 52-year-old with dense breast tissue, a BRCA2 variant, and a mother diagnosed at 48. Treating them identically — the same two-yearly mammogram, the same invitation letter — is not equitable care.

Dense breast tissue matters for two reasons that compound each other. First, dense tissue is an independent risk factor for breast cancer. Women with dense breasts face a significantly elevated risk of developing breast cancer compared to women with fatty breasts. Second, dense tissue appears white on a mammogram — the same colour as a tumour. Cancers can be missed entirely in women whose screening should be most intensive.

Notifying women of their breast density, and using that information to guide follow-up, is a meaningful step toward a system that accounts for this.

The complexity is real

Risk stratification at population scale is harder than it sounds. It requires more GP involvement — women who learn they have elevated risk need someone to talk to about what that means, what the next step is, whether a referral to a familial cancer centre is appropriate. That requires time and infrastructure that the general practice system is not currently resourced to provide at scale.

Polygenic risk scores — which use patterns of multiple common genetic variants to estimate breast cancer risk — are promising but not yet validated for routine clinical use in Australia at population level. The technology exists; the framework for acting on the results within a healthcare setting is still being developed.

AI mammography tools are being trialled, not deployed. Early results from trials in Victoria and South Australia are encouraging, but these tools need to demonstrate accuracy across diverse Australian populations — including women of different ethnic backgrounds, where the validation data is thinner.

The ten-year timeline reflects real implementation challenges, not bureaucratic stalling.

My two cents

If you are 40 or over and have been attending BreastScreen, here is the thing worth knowing this week: you may not have been told your breast density, because the current system does not require it. That is about to change — but slowly.

You do not have to wait. At your next mammogram, you can ask the radiographer about your breast density classification. It is in the report. If your density is heterogeneous or extremely dense, that is information your GP should know about.

If you have any first-degree relatives — mother, sister, daughter — who have had breast cancer, or any relatives with ovarian cancer, a conversation with your GP about family history risk is warranted now, not when the national rollout arrives. iPrevent, developed at Peter Mac, is an Australian-developed tool that lets GPs calculate personalised screening recommendations based on combined risk factors — family history, breast density, age at first period, parity, and more.

The shift toward risk-stratified screening means that “I get my two-yearly mammogram” is no longer the full answer to breast cancer surveillance. For some women, it is not enough. Finding out which category you are in, and getting the level of surveillance that matches your actual risk, is the conversation this review is trying to prompt.

Verdict: yes — worth knowing about, particularly if you are approaching or in the 40–60 age bracket.

Sources cited

  1. Dense breasts or breast cancer in the family? What screening changes mean for you. Jennifer Stone, The Conversation, 7 August 2026. https://theconversation.com/dense-breasts-or-breast-cancer-in-the-family-what-screening-changes-mean-for-you-289221
  2. BreastScreen Australia national program. https://www.breastscreen.org.au
  3. iPrevent — Peter MacCallum Cancer Centre familial cancer resources. https://www.petermac.org/services/support-services/familial-cancer-centre

Frequently asked questions

  • What is breast density and why does it matter?

    Breast density describes the proportion of glandular and connective tissue relative to fatty tissue in the breast. Dense breast tissue appears white on a mammogram — the same colour as a tumour — which means cancers can be harder to detect in women with dense breasts. Dense tissue is also an independent risk factor for developing breast cancer. Women are classified into four density categories; those in the higher two categories are at meaningfully elevated risk.

  • What is iPrevent and how does a GP use it?

    iPrevent is a risk assessment tool developed at the Peter MacCallum Cancer Centre in Melbourne. It allows GPs to enter information about a patient's family history, breast density, and other risk factors and generate a personalised risk estimate and screening recommendation. It is designed for use in the GP consultation, not as a self-assessment tool, because interpreting the output and discussing follow-up options requires clinical context.